These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31366977)

  • 1. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.
    Estival A; Sanz C; Ramirez JL; Velarde JM; Domenech M; Carrato C; de Las Peñas R; Gil-Gil M; Sepúlveda J; Armengol R; Cardiel I; Berrocal A; Luque R; Herrero A; Balana C
    Sci Rep; 2019 Jul; 9(1):11125. PubMed ID: 31366977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
    Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
    Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
    Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
    Wang L; Li Z; Liu C; Chen L; Liu L; Hu Z; Zhao L; Lu D; Teng L
    Pathol Res Pract; 2017 Dec; 213(12):1489-1493. PubMed ID: 29103769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR.
    Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A
    Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Johannessen LE; Brandal P; Myklebust TÅ; Heim S; Micci F; Panagopoulos I
    Cancer Genomics Proteomics; 2018; 15(6):437-446. PubMed ID: 30343277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive markers for MGMT promoter methylation in glioblastomas.
    Kanazawa T; Minami Y; Jinzaki M; Toda M; Yoshida K; Sasaki H
    Neurosurg Rev; 2019 Dec; 42(4):867-876. PubMed ID: 30673883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
    Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
    J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
    Dahlrot RH; Larsen P; Boldt HB; Kreutzfeldt MS; Hansen S; Hjelmborg JB; Kristensen BW
    J Neuropathol Exp Neurol; 2019 Jul; 78(7):633-640. PubMed ID: 31058280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D
    Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
    Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
    Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.